Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Intellipharmaceutics Intl In (IPCIQ)

0 + Investors. Track Smart Money conviction in IPCIQ. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -1
Streak
1Q ▼
Buyers last Q
43%

Smart Money Signals — IPCIQ

Based on 4 hedge funds · latest filing: 2018 Q4 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 1Q
For 1 consecutive quarter, more hedge funds reduced or closed their IPCIQ positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 80% of 0.5Y peak

80% of all-time peak
4 funds currently hold this stock — 80% of the 0.5-year high of 5 funds (reached 2018 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
🟠

More sellers than buyers — 43% buying

3 buying4 selling
Last quarter: 4 funds reduced or exited vs 3 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
💎

Buying through price weakness — shares +148%, value -78%

Value
-77%
Shares
+148%
Last quarter: funds added +148% more shares while total portfolio value only changed -78%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
2.4
out of 10
Low Exit Risk
Exit risk score 2.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — IPCIQ

In 2018 Q4, 3 hedge funds were net buyers of IPCIQ (3 opened a brand-new position), while 4 reduced or exited (4 sold completely) — a 43% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: -1 funds (more exits than new entries). Total institutional holders: 4.

Hedge Fund Ownership: IPCIQ

How many hedge funds hold IPCIQ — quarterly history vs. share price
Quarterly hedge fund ownership of IPCIQ vs. share price

Market Analysis: IPCIQ

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: IPCIQ

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Intellipharmaceutics Intl In (IPCIQ) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much IPCIQ has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 81d ago
IPCIQ
+0.0%
XLV
+2.1%

IPCIQ outperformed XLV by -2.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 36d ago
IPCIQ
+0.0%
XLV
+3.2%

Since the filing became public, IPCIQ outperformed XLV by -3.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

0 top-rated funds 0 high-conviction
Consensus
0.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: IPCIQ
0 + Investors

Track Smart Money conviction in IPCIQ. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 0 0 -
13F Shares 0 0 -
Total Value $0 $0 -
New Positions 0 0 -
Increased Positions 0 0 -
Closed Positions 0 0 -
Reduced Positions 0 0 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: IPCIQ

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

0 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IPCIQ. Verified SEC 13F-HR filings.

QUARTER:
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Intellipharmaceutics Intl In (IPCIQ)

What does the Smart Money Trend signal show for IPCIQ?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their IPCIQ positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for IPCIQ?

More sellers than buyers — 43% buying: Last quarter: 4 funds reduced or exited vs 3 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

Is it too late to buy Intellipharmaceutics Intl In (IPCIQ) following the 2026 Q1 hedge fund 13F filings?

As of today, IPCIQ has moved +0.0% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of -3.2%. Since the quarter end (March 31, 2026), IPCIQ has gained +0.0% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →